Biotechnology Market Size to Hit USD 5.71 Trillion by 2034

Biotechnology Market Key Takeaways

• In terms of revenue, the global biotechnology market was valued at USD 1.55 trillion in 2024.
• It is projected to reach USD 5.71 trillion by 2034.
• The market is expected to grow at a CAGR of 13.90% from 2025 to 2034.
• North America accounted for a revenue share of 37.42% in 2024.
• Asia Pacific is expected to grow at the fastest CAGR of 14.8% during the period.
• By application, the bio-pharmacy segment captured the biggest market share of 42% in 2024.
• By application, bio-informatics segments segment is expected to grow at a solid CAGR of 13.2% during the forecast period
• By technology, the tissue engineering and regeneration segment held the highest market share of 19.17% in 2024.
• By technology, the chromatography segment is projected to grow at a solid CAGR of 15.1% during the forecast period

Market Overview

Government Initiatives Driving the Biotechnology Sector

Governments around the world are actively implementing strategic initiatives to support the growth and global competitiveness of the biotechnology industry. These efforts aim to create a favorable environment for innovation, research, and commercial development.

In India, Union Minister Dr. Jitendra Singh, in an interview with Doordarshan News, highlighted that the year 2025 is expected to be a pivotal one for India in the global biotechnology space. He pointed to the launch of the BIO-E3 policy under the Modi Government 3.0 as a major milestone in shaping India’s biotechnology future and establishing the country as a global leader in the sector.

In the United States, Congress allocated funding to support the Agricultural Biotechnology Education and Outreach Initiative, committing $7.5 million to promote public education on agricultural biotechnology and biotechnology-derived food and feed products. This initiative is a collaborative effort involving the U.S. Food and Drug Administration, the U.S. Department of Agriculture, and the Environmental Protection Agency.

In Europe, the European Commission launched the EU Biotech and Biomanufacturing Initiative with the aim of strengthening the region’s biotech competitiveness and modernizing industrial processes. This initiative outlines eight key actions, including the proposal of an EU Biotech Act, the creation of an EU Biotech Hub, simplification of regulatory frameworks, and improved funding mechanisms. These measures are intended to support investment and innovation while shaping future policies such as the EU Bioeconomy Strategy and the ongoing Pharma Package discussions.

Biotechnology Market Growth Factors

The biotechnology market is experiencing robust growth, driven by advancements across multiple disciplines such as biochemistry, genetics, and molecular biology. The continuous development of innovative products and technologies in medical, agricultural, and industrial biotechnology is fueling widespread adoption globally.

One of the key growth drivers is the increasing governmental support in emerging economies like China, India, and Japan. These initiatives aim to streamline regulatory pathways, improve reimbursement frameworks, standardize clinical trials, and accelerate product approvals—collectively creating a favorable environment for biotech expansion.

In agriculture, companies are focusing on upgrading technologies through advanced breeding techniques, gene sequencing, and the development of crops with stacked traits. These innovations aim to improve productivity and sustainability, further expanding biotechnology applications in the agri-tech sector.

The rising prevalence of genetic disorders and infectious diseases, along with breakthroughs in diagnostic technologies such as Polymerase Chain Reaction (PCR), miniaturized instruments, and robotics, are also key contributors to market growth. Increased funding, grants, and private investments in R&D are enabling faster innovation and commercialization of biotech solutions.

Genomic analytic techniques, particularly in the detection of pathogens and genetic mutations, are being rapidly adopted for the diagnosis of diseases such as HIV, malaria, tuberculosis, and various inherited disorders. The growing reliance on PCR and other molecular diagnostic tools is boosting demand for biotech-based clinical diagnostics.

Opportunity

Precision Medicine and Sustainable Agriculture

The rapid advancement of genomics, proteomics, and bioinformatics is opening substantial opportunities in the development of precision medicine tailored to individual genetic profiles. Personalized therapies offer the potential to enhance treatment efficacy, reduce adverse effects, and significantly improve patient outcomes. Companies specializing in genetic testing, biomarker discovery, and targeted therapeutic solutions are well-positioned to capitalize on this growing demand.

In parallel, the global shift toward sustainable agriculture presents another major opportunity for the biotechnology sector. The development of genetically modified crops that are resilient to climate change, pests, and disease can play a crucial role in improving food security and promoting environmentally friendly farming practices. Biotech firms that focus on creating next-generation agricultural solutions will find increasing relevance in both developed and emerging markets.

Biotechnology Market Key Players

• Lonza
• AstraZeneca
• Pfizer Inc.
• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd.
• Biogen
• CELGENE Corporation
• Sanofi
• Abbott
• Novartis AG

Recent Developments

• In May 2025, Layn Natural Ingredients has recently launched an upgraded biotechnology facility, which will greatly improve the company’s abilities in precision fermentation and enzyme manufacturing. The initial innovation to come from the facility is Galacan, an advanced beta glucan. The company states that, in contrast to beta glucans sourced from oats, yeast, algae, or mushrooms, Galacan is produced through precision fermentation, resulting in a distinct spiral-shaped heteropolysaccharide.
• In May 2025, Nestlé announced a strategic overhaul of its worldwide R&D activities, featuring improved proficiency in biotechnology and the establishment of a new deep tech center in Orbe, located in the canton of Vaud. These modifications seek to enhance the company’s innovation pipeline and improve operational efficiency.
• In January 2025, Biosphere, a startup creating innovative bioproduction systems, has come out of stealth  with the introduction of a revolutionary UV-sterilized bioreactor. This innovation represents a significant breakthrough for industrial biotechnology, enabling a substantial decrease in the capital intensity that has hindered the sector for many years.